Seeking Alpha

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its...

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials. (previous)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)